MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
Bristol-Myers Squibb Company Operating Cash Flow 2011-2026 | BMY
Annual Operating Cash Flow Bristol-Myers Squibb Company
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.2 B | 13.9 B | 13.1 B | 16.2 B | 14.1 B | 8.21 B | 7.07 B | 5.28 B | 3.06 B | 2.1 B | 3.15 B | 3.54 B | 6.94 B | 4.84 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 16.2 B | 2.1 B | 8.33 B |
Quarterly Operating Cash Flow Bristol-Myers Squibb Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 1.95 B | - | - | 2.83 B | - | - | 2.97 B | - | 9.76 B | - | 3.81 B | - | 12.2 B | - | 3.82 B | - | 10.7 B | 8.43 B | 3.94 B | - | 6.03 B | 3.47 B | 1.39 B | - | 3.51 B | 2.23 B | 1.18 B | - | 4.16 B | 2.44 B | 861 M | - | 1.62 B | 211 M | -228 M | - | 1.22 B | 697 M | 626 M | - | 2.58 B | 1.67 B | 617 M | - | 2.14 B | 1.08 B | -428 M | - | 6.1 B | 1.52 B | 387 M | - | 3.27 B | 1.57 B | 481 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 12.2 B | -428 M | 2.99 B |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
-7.8 M | - | -10.17 % | $ 12.2 K |  USA |
 |
Aeglea BioTherapeutics
AGLE
|
-157 M | - | - | $ 1.01 B | USA |
 |
Adagene
ADAG
|
-29.7 M | $ 1.65 | 7.91 % | $ 92.9 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 3.59 | 1.99 % | $ 8.64 B |  Australia |
 |
Arrowhead Pharmaceuticals
ARWR
|
180 M | $ 66.05 | 2.3 % | $ 8.83 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
-206 M | $ 1.52 | -16.3 % | $ 388 M |  Britain |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Biogen
BIIB
|
2.88 B | $ 184.48 | -1.67 % | $ 26.9 B | USA |
 |
AVROBIO
AVRO
|
-63.2 M | - | 1083.1 % | $ 745 M | USA |
 |
BioNTech SE
BNTX
|
890 M | $ 102.17 | 2.32 % | $ 27.2 B | Germany |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M | Britain |
 |
AstraZeneca PLC
AZN
|
5.96 B | $ 93.52 | -1.2 % | $ 96.9 B | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
-7.64 M | $ 4.25 | 1.67 % | $ 9.25 B |  Israel |
 |
BeiGene, Ltd.
BGNE
|
-141 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
-25.8 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-47.5 M | - | -7.31 % | $ 87 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-418 M | $ 207.49 | 2.22 % | $ 5 B |  Danmark |
 |
Codiak BioSciences
CDAK
|
-74.1 M | - | -55.98 % | $ 2.15 M | USA |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Cerevel Therapeutics Holdings
CERE
|
-342 M | - | - | $ 7.29 B | USA |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M |  Canada |
 |
Zai Lab Limited
ZLAB
|
-215 M | $ 18.37 | -0.97 % | $ 18.2 B | China |
 |
Coherus BioSciences
CHRS
|
-175 M | $ 1.61 | -5.03 % | $ 152 M | USA |
 |
Catalyst Biosciences
CBIO
|
25.9 M | $ 10.84 | 0.46 % | $ 714 M | USA |
 |
Caladrius Biosciences
CLBS
|
-19.4 M | - | -16.75 % | $ 25.8 M | USA |
 |
Celldex Therapeutics
CLDX
|
-158 M | $ 25.59 | -6.54 % | $ 1.65 M | USA |
 |
Cellectis S.A.
CLLS
|
-105 M | $ 4.22 | -4.2 % | $ 116 M | France |
 |
Clearside Biomedical
CLSD
|
-18.1 M | - | - | $ 25.3 M | USA |
 |
Chimerix
CMRX
|
-69.1 M | - | - | $ 756 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-141 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Corcept Therapeutics Incorporated
CORT
|
198 M | $ 37.35 | -0.4 % | $ 3.86 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
240 M | $ 23.18 | 2.02 % | $ 2.75 B | USA |
 |
AIkido Pharma
AIKI
|
-15.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-67.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-226 M | $ 55.11 | 3.49 % | $ 4.45 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-143 M | $ 55.17 | 2.47 % | $ 4.65 B |  Schweiz |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | Israel |
 |
Zentalis Pharmaceuticals
ZNTL
|
-208 M | $ 3.53 | -5.75 % | $ 231 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
213 M | $ 29.43 | 6.09 % | $ 1.43 B | USA |